Abstract: Disclosed are example embodiments of systems, method, and devices for generating audio assets. The example method includes receiving an input including at least one of audio, text, video, Java Script Object Notation (JSON), Extensible Markup Language (XML), Really Simple Syndication (RSS). The example method includes receiving configuration inputs including at least one of configure language, gender, and persona. The example method includes preparing for processing based on the at least one of configure language, gender, and persona. The example method includes processing the input based on the configuration inputs, the processing including at least one of transcribing, translating, brand safety, enrichment, generating custom Speech Synthesis Markup Language (SSML), and including generating an audio clip. The example method includes delivering the audio clip.

Abstract: The present invention relates to a two-part device, wherein a first part is an engineered antigen-presenting cell system (eAPCS), and a second part is an engineered TCR-presenting cell system (eTPCS).

Abstract: The present invention relates to a two-part device, wherein a first part is a multicomponent TCR ORF reconstitution and engineering system (TORES), and a second part is a multicomponent engineered TCR-presenting cell system (eTPCS).

Abstract: A combined system comprising two separate components, wherein the first component is a tag-exchange donor vector (TEDV) encoding a first cell surface tag (CST) exon flanked by a 3? intron fragment, and a gene of interest (GOI) in the antisense orientation, and the second component is an engineered cell containing within its genome a tag-exchange receiver site (TERS), encoding a second CST exon adjoined by a full intron sequence to an exon encoding a transmembrane domain, and also encoding a reporter gene in the antisense orientation, wherein paired recombinase mediated cassette exchange (RMCE) elements are included in the TEDV and TERS such that execution of RMCE between the TEDV and TERS results in exchange of the reporter element for the GOI encoded by the TEDV, and exchange of the first CST exon for the second CST exon, such that the derivative engineered cell now expresses the first CST and GOI, in place of the second CST and the reporter gene.

Abstract: The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for recombinase mediated exchange (RMCE).

Abstract: A combined system comprising two separate components, wherein a first component is a vector carrying variable and constant (V-C) T-cell receptor (TCR) gene segments, and a second component is a vector carrying joining (J) TCR gene segments. The combined system may be modified so that said first component is a modified V-C entry vector encoding a first TCR chain, the system further comprises a fourth and a fifth component, wherein the fourth component comprises a Bidirectional Terminator (BiT) donor vector, and the fifth component comprises a modified V-C entry vector encoding a second TCR chain complimentary to said first TCR chain.

Abstract: The present invention relates to a two-part device, wherein a first part is an engineered antigen-presenting cell system (eAPCS), and a second part is an engineered TCR-presenting cell system (eTPCS).

Abstract: The present invention relates to a multicomponent system wherein a first component is an engineered TCR-presenting cell (eTPC), designated component A, wherein component A lacks endogenous surface expression of at least one family of analyte antigen-presenting complexes (aAPX) and/or analyte antigenic molecule (aAM), and a second component is a genetic donor vector, designated component C, for delivery of ORF encoding analyte TCR chains.

Abstract: The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver GO sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for re-combinase mediated exchange (RMCE).

Abstract: The present invention relates to a two-part device, wherein a first part is a multicomponent TCR ORF reconstitution and engineering system (TORES), and a second part is a multicomponent engineered TCR-presenting cell system (eTPCS).

Abstract: The invention relates to a genetically engineered bacterium having an enzyme that converts acetyl-CoA to acetoacetyl-CoA, an enzyme that converts acetoacetyl-CoA to 3-hydroxybutyryl-CoA, and an enzyme that converts 3-hydroxybutyryl-CoA to 3-hydroxybutyrate. The bacterium may also have enzymes to produce other downstream products, such as 3-hydroxybutyryaldehyde, and 1,3-butanediol. Typically, the bacterium is capable of producing these products from a gaseous substrate, such as syngas or an industrial waste gas.

Abstract: The invention relates to a genetically engineered bacterium having an enzyme that converts acetyl-CoA to acetoacetyl-CoA, an enzyme that converts acetoacetyl-CoA to 3-hydroxybutyryl-CoA, and an enzyme that converts 3-hydroxybutyryl-CoA to 3-hydroxybutyrate. The bacterium may also have enzymes to produce other downstream products, such as 3-hydroxybutyryaldehyde, and 1,3-butanediol. Typically, the bacterium is capable of producing these products from a gaseous substrate, such as syngas or an industrial waste gas.

Abstract: The invention relates to a genetically engineered bacterium comprising an energy-generating fermentation pathway and methods related thereto. In particular, the invention provides a bacterium comprising a phosphate butyryltransferase (Ptb) and a butyrate kinase (Buk) (Ptb-Buk) that act on non-native substrates to produce a wide variety of products and intermediates. In certain embodiments, the invention relates to the introduction of Ptb-Buk into a C1-fixing microoorgansim capable of producing products from a gaseous substrate.

Abstract: The invention relates to a genetically engineered bacterium comprising an energy-generating fermentation pathway and methods related thereto. In particular, the invention provides a bacterium comprising a phosphate butyryltransferase (Ptb) and a butyrate kinase (Buk) (Ptb-Buk) that act on non-native substrates to produce a wide variety of products and intermediates. In certain embodiments, the invention relates to the introduction of Ptb-Buk into a C1-fixing microoorgansim capable of producing products from a gaseous substrate.

Abstract: The invention provides a recombinant, acetogenic, carboxydotrophic bacterium that lacks secondary alcohol dehydrogenase or comprises an inactivated secondary alcohol dehydrogenase. The inactivated secondary alcohol dehydrogenase may be encoded by a secondary alcohol dehydrogenase gene comprising an inactivating mutation that reduces the ability of the bacterium to convert acetone to isopropanol and to convert methyl ethyl ketone to 2-butanol. Since a bacterium that lacks secondary alcohol dehydrogenase or comprises an inactivated secondary alcohol dehydrogenase accumulates carbonyl-containing compounds, the invention also provides a method of producing carbonyl-containing compounds, such as acetone and methyl ethyl ketone.